Q8

Q8, an effective antiangiogenic drug, is a CysLt1 antagonist (IC50 of 4.9 μM) . Q8 is sufficient to reduce cellular levels of NF-κB and calpain-2 and secreted levels of the proangiogenic proteins intercellular adhesion molecule-1, vascular cell adhesion protein-1, and VEGF[1].

Product Specifications

CAS Number

[1541762-55-3]

UNSPSC

12352005

Target

Leukotriene Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/q8.html

Smiles

OC1=CC=C(O)C=C1/C=C/C2=NC3=CC=CC=C3C=C2.Cl

Molecular Formula

C17H14ClNO2

Molecular Weight

299.75

References & Citations

[1]Clare T Butler, et al. A Quininib Analogue and Cysteinyl Leukotriene Receptor Antagonist Inhibits Vascular Endothelial Growth Factor (VEGF) -independent Angiogenesis and Exerts an Additive Antiangiogenic Response with Bevacizumab. J Biol Chem. 2017 Mar 3;292 (9) :3552-3567.